SCHEMBL1628532

SCHEMBL1628532

Cc1ccc(N(C)S(C)(=O)=O)cc1C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.42
PGR P06401 1/20 0.39
TSHR P16473 1/20 0.37
ALDH1A1 P00352 6/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CSF1R P07333 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 3/20 0.35
USP2 O75604 1/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
GAA P10253 1/20 0.34
STAT1 P42224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6863864 0.82 MEN1 (0.39) NPSR1PGRTSHRALDH1A1HTT
SCHEMBL6862061 0.80 ALDH1A1 (0.49) PGRALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5017012 0.78 TSHR (0.45) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL1371755 0.74 NPSR1 (0.44) NPSR1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL13345042 0.74 NPSR1 (0.44) NPSR1ALDH1A1HTTMEN1KMT2A
SCHEMBL12595919 0.72 EPAS1 (0.46) TSHRALDH1A1SMN1; SMN2LMNA
SCHEMBL1291291 0.71 ALDH1A1 (0.47) PGRALDH1A1HTTMEN1KMT2A
SCHEMBL6861888 0.70 PGR (0.36) PGRALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL6151699 0.70 SLC6A4 (0.46) TSHRALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL17790348 0.70 NPSR1 (0.41) NPSR1ALDH1A1HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2025-07-03 US disclosed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 US disclosed
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2022-08-11 US disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
EP-2146779-B1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2016-08-10 EP disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 US disclosed
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH VERASTEM, INC. (US) 2015-03-19 US disclosed
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH LUZZIO MICHAEL JOSEPH (US) 2014-04-10 US disclosed
US-8440822-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. 2013-05-14 US disclosed
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER, INC. 2013-01-03 US disclosed
US-8247411-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2012-08-21 US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
EP-2146779-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2010-01-27 EP disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed
WO-2008129380-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NPSR1 866/4885PGR 2818/4885TSHR 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.